Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Core Insights - Acumen Pharmaceuticals has initiated a Phase 1 pharmacokinetic study for its subcutaneous formulation of sabirnetug (ACU193), targeting soluble amyloid beta oligomers (AβOs) for Alzheimer's disease treatment [1][2] - The subcutaneous formulation utilizes Halozyme's ENHANZE® technology, which enhances drug delivery by allowing larger volumes to be administered subcutaneously [1][6] - Sabirnetug is the first humanized monoclonal antibody to show selective engagement with AβOs in Alzheimer's patients, aiming to address early neurodegenerative processes [2][4] Company Overview - Acumen Pharmaceuticals is focused on developing therapies for Alzheimer's disease, specifically targeting toxic soluble AβOs, which are implicated in the disease's pathology [8] - The company is currently conducting the ALTITUDE-AD Phase 2 clinical trial to evaluate the efficacy and safety of intravenous sabirnetug in early Alzheimer's patients [2][8] Clinical Trial Insights - The Phase 1 INTERCEPT-AD trial demonstrated that intravenous sabirnetug is well tolerated, with a favorable safety profile and significant amyloid plaque reduction [3][5] - The INTERCEPT-AD trial involved 65 participants with early symptomatic Alzheimer's disease and aimed to establish safety, tolerability, and pharmacokinetics of the drug [5] Technology Utilization - Halozyme's ENHANZE® technology allows for rapid subcutaneous delivery of biologics, potentially reducing the need for multiple injections and improving patient convenience [6][7]